DK1175402T3 - Piperidinderivater, der er nyttige som CCR5-antagonister - Google Patents

Piperidinderivater, der er nyttige som CCR5-antagonister

Info

Publication number
DK1175402T3
DK1175402T3 DK00926487T DK00926487T DK1175402T3 DK 1175402 T3 DK1175402 T3 DK 1175402T3 DK 00926487 T DK00926487 T DK 00926487T DK 00926487 T DK00926487 T DK 00926487T DK 1175402 T3 DK1175402 T3 DK 1175402T3
Authority
DK
Denmark
Prior art keywords
derivatives useful
piperidine derivatives
ccr5 antagonists
ccr5
antagonists
Prior art date
Application number
DK00926487T
Other languages
Danish (da)
English (en)
Inventor
John W Clader
Hubert B Josien
Stuart W Mccombie
Michael W Miller
Bernard R Neustadt
Anandan Palani
Jayaram R Tagat
Susan F Vice
Mark A Laughlin
Bahige M Baroudy
Brian A Mckittrick
Ruo Steensma
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1175402T3 publication Critical patent/DK1175402T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00926487T 1999-05-04 2000-05-01 Piperidinderivater, der er nyttige som CCR5-antagonister DK1175402T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30518799A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
DK1175402T3 true DK1175402T3 (da) 2005-11-21

Family

ID=23179704

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00926487T DK1175402T3 (da) 1999-05-04 2000-05-01 Piperidinderivater, der er nyttige som CCR5-antagonister

Country Status (32)

Country Link
EP (2) EP1175402B1 (cs)
JP (3) JP3894729B2 (cs)
KR (1) KR100439357B1 (cs)
CN (2) CN1151131C (cs)
AR (1) AR023939A1 (cs)
AT (1) ATE299866T1 (cs)
AU (2) AU780983B2 (cs)
BR (1) BR0010607A (cs)
CA (1) CA2371587C (cs)
CO (1) CO5170522A1 (cs)
CZ (1) CZ301161B6 (cs)
DE (1) DE60021371T2 (cs)
DK (1) DK1175402T3 (cs)
EG (1) EG24533A (cs)
ES (1) ES2246233T3 (cs)
HK (1) HK1039330B (cs)
HU (1) HUP0203528A3 (cs)
IL (1) IL145742A0 (cs)
MY (1) MY141473A (cs)
NO (1) NO322044B1 (cs)
NZ (1) NZ514675A (cs)
PE (1) PE20010113A1 (cs)
PL (1) PL203117B1 (cs)
PT (1) PT1175402E (cs)
RU (2) RU2266281C2 (cs)
SA (1) SA00210270B1 (cs)
SI (1) SI1175402T1 (cs)
SK (1) SK286968B6 (cs)
TR (2) TR200103213T2 (cs)
TW (1) TWI283666B (cs)
WO (1) WO2000066559A1 (cs)
ZA (1) ZA200108867B (cs)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
RU2316553C2 (ru) 2001-03-29 2008-02-10 Шеринг Корпорейшн Производные пиперидина, фармацевтическая композиция на их основе и применение
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
CA2452597A1 (en) * 2001-07-02 2003-01-16 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
US6914142B2 (en) 2001-10-15 2005-07-05 Schering Corporation Synthesis of (4-bromopnenyl)(4-piperidyl)methanone-(Z)-O-ethyloxime and salts
US6818773B2 (en) 2001-10-15 2004-11-16 Schering Corporation Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine
JP2005518424A (ja) 2001-11-29 2005-06-23 シェーリング　コーポレイション Ａｉｄｓおよび関連するｈｉｖ感染の処置のためのｃｃｒ５−アンタゴニストとしての４（（ｚ）−（４−ブロモフェニル）エトキシイミノ）メチル）−１’−（（２，４−ジメチル−１−オキシド−３−ピリジニルカルボニル）−４’−メチル−１，４’ビピペリジンの薬学的塩の調製
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
EP1490352A1 (en) 2002-03-29 2004-12-29 Schering Corporation Synthesis of piperidine and piperazine compounds as ccr5 antagonists
WO2003090748A1 (fr) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
JP2004107298A (ja) * 2002-09-20 2004-04-08 Takeda Chem Ind Ltd ウレア化合物およびその用途
WO2004026833A1 (ja) * 2002-09-20 2004-04-01 Takeda Pharmaceutical Company Limited 環状アミン化合物、その製造法および用途
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
CA2509711A1 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
KR101078505B1 (ko) 2003-03-14 2011-10-31 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US20070043079A1 (en) * 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
CN1835944A (zh) * 2003-06-13 2006-09-20 舍林股份公司 作为ccr－5拮抗剂的喹啉酰胺衍生物
WO2005007608A2 (en) 2003-07-10 2005-01-27 Schering Corporation Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters
SE0302956D0 (sv) * 2003-11-07 2003-11-07 Astrazeneca Ab Chemical compounds
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2007522160A (ja) 2004-02-10 2007-08-09 エフ．ホフマン−ラ　ロシュ　アーゲー ケモカインｃｃｒ５受容体モジュレーター
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
KR101235090B1 (ko) 2004-04-13 2013-02-20 인사이트 코포레이션 케모킨 수용체 길항제로서의 피페라지닐피페리딘 유도체
PT1761542E (pt) 2004-06-09 2008-03-26 Hoffmann La Roche Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais
EP1790637B1 (en) 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US20090124635A1 (en) * 2005-01-20 2009-05-14 Pfizer Inc. Chemical compounds
KR20070107046A (ko) * 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 지닌 헤테로사이클릭 치환된피페라진
BRPI0609251A2 (pt) * 2005-02-23 2010-03-09 Schering Corp derivados de piperidinil piperazina úteis como inibidores de receptores de quimiocinas
JP4822367B2 (ja) * 2005-02-23 2011-11-24 シェーリング コーポレイション ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
PL1942108T3 (pl) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Związek zawierający grupę zasadową i jego zastosowanie
DK1961744T3 (da) 2005-11-18 2013-07-15 Ono Pharmaceutical Co Forbindelse indeholdende basiske grupper samt anvendelse deraf
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP2059515A2 (en) * 2006-04-12 2009-05-20 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
MX2008013431A (es) 2006-04-21 2008-11-04 Novartis Ag Derivados de purina para utilizarse como agonistas del receptor de adenosina a2a.
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
DE602007013573D1 (de) 2006-08-16 2011-05-12 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CA2671478C (en) 2006-12-13 2015-02-17 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
EA016199B1 (ru) 2007-01-10 2012-03-30 Айрм Ллк Соединения и композиции как ингибиторы активирующей канал протеазы
MX2009010503A (es) 2007-03-29 2009-10-19 Hoffmann La Roche Compuestos heterociclicos antiviricos.
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
MY152955A (en) 2007-12-10 2014-12-15 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
EP2259772A2 (en) * 2008-02-29 2010-12-15 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012003709B1 (pt) 2009-08-17 2021-05-18 Intellikine Llc compostos heterocíclicos e usos dos mesmos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
KR101491938B1 (ko) 2010-07-14 2015-02-10 노파르티스 아게 Ｉｐ 수용체 효능제 헤테로시클릭 화합물
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
GB2511685A (en) 2011-11-18 2014-09-10 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US9174985B2 (en) 2012-01-13 2015-11-03 Novartis Ag Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US8937069B2 (en) 2012-01-13 2015-01-20 Novartis Ag Substituted pyrrolo[2,3-B]pyrazine compounds and their use
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
EP2956455B1 (en) 2013-02-13 2017-05-17 Novartis AG Ip receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
JP2017501164A (ja) 2013-12-19 2017-01-12 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピペリジニルテトラヒドロキノリン類
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CN106029657A (zh) 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
WO2015091415A1 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
JP3068206B2 (ja) * 1996-07-10 2000-07-24 シェーリング コーポレイション ムスカリン様アンタゴニストとしての１，４―ジ―置換ピペリジン
WO1998004125A1 (en) * 1996-07-25 1998-02-05 Terence George Mackay Improvements in or relating to fishing
ATE297381T1 (de) * 1996-08-15 2005-06-15 Schering Corp Ether-muskarinantagonisten
EP1003514A4 (en) * 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS

Also Published As

Publication number Publication date
PL203117B1 (pl) 2009-08-31
RU2266281C2 (ru) 2005-12-20
IL145742A0 (en) 2002-07-25
NO20015365L (no) 2002-01-03
MY141473A (en) 2010-04-30
KR20020019906A (ko) 2002-03-13
ATE299866T1 (de) 2005-08-15
AU780983B2 (en) 2005-04-28
SK286968B6 (sk) 2009-08-06
EP1175402A1 (en) 2002-01-30
HK1039330A1 (en) 2002-04-19
ZA200108867B (en) 2003-03-26
NO20015365D0 (no) 2001-11-02
EG24533A (en) 2009-08-30
HUP0203528A2 (hu) 2003-02-28
JP2002543186A (ja) 2002-12-17
CZ20013941A3 (cs) 2002-04-17
JP2006225407A (ja) 2006-08-31
CA2371587C (en) 2005-09-13
AU2005202358A1 (en) 2005-06-23
CO5170522A1 (es) 2002-06-27
AR023939A1 (es) 2002-09-04
EP1659111A3 (en) 2007-05-09
PE20010113A1 (es) 2001-02-05
CN1151131C (zh) 2004-05-26
DE60021371D1 (de) 2005-08-25
HUP0203528A3 (en) 2003-11-28
SA00210270B1 (ar) 2006-09-04
SK15672001A3 (sk) 2002-06-04
EP1175402B1 (en) 2005-07-20
NZ514675A (en) 2004-05-28
BR0010607A (pt) 2002-02-13
CN1349504A (zh) 2002-05-15
SI1175402T1 (en) 2005-10-31
TR200103213T2 (tr) 2002-03-21
CN1524527A (zh) 2004-09-01
JP3894729B2 (ja) 2007-03-22
EP1659111A2 (en) 2006-05-24
DE60021371T2 (de) 2006-04-27
RU2005120376A (ru) 2006-12-27
KR100439357B1 (ko) 2004-07-07
JP2011219493A (ja) 2011-11-04
CA2371587A1 (en) 2000-11-09
TR200402496T2 (tr) 2005-01-24
PT1175402E (pt) 2005-11-30
NO322044B1 (no) 2006-08-07
ES2246233T3 (es) 2006-02-16
WO2000066559A1 (en) 2000-11-09
HK1039330B (en) 2005-12-09
CZ301161B6 (cs) 2009-11-18
AU2005202358B2 (en) 2008-01-10
AU4501000A (en) 2000-11-17
TWI283666B (en) 2007-07-11
PL351412A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
DK1175402T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister
DK1175401T3 (da) Piperazinderivater, der er nyttige som CCR5-antagonister
NO20021450L (no) Cykliske aminforbindelser som CCR5-antagonister
DK1218359T3 (da) Piperazinforbindelser som tachykininantagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20021459D0 (no) Piperazin-derivater som 5-HT1B-antagonister
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
DK1049689T3 (da) 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
NO20023485L (no) 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
DK1421075T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV
NO20023293D0 (no) Piperidin- og piperazinderivater som virker som 5-HT2A- reseptorantagonister
NO20032142D0 (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
AU2002223968A1 (en) Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK0964863T3 (da) Oxazolidinoner som 5-HT2A-antagonister
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
NO20015920D0 (no) Etansulfonyl-piperidin-derivater
DK1015446T3 (da) 4-(Piperidinyl)-1H-2-benzopyranderivater, der er nyttige som antipsykotiske midler
DK1456197T3 (da) Piperidin-2,6-dioner, som er substitueret heterocyklisk i 3-stillingen
DK1077942T3 (da) Carboxysubstituerede carboxamidderivater som tachykininreceptorantagonister
HK1082913A (en) Piperidine derivatives as ccr5 antagonists
HK1085118A (en) Piperidine derivatives as ccr5 antagonists